Treatment for Locoregionally Recurrent Head and Neck Cancers
10.3342/kjorl-hns.2022.00087
- Author:
Minsu KWON
1
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- Publication Type:Review
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2022;65(3):133-142
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The locoregional recurrence rate after treatment of head and neck cancer (HNC) is known to be about 40%, and recurrence of cancer is the major factor directly related to the survival of patients. Recurrent HNC has different biological characteristics and tumor microenvironment from those of index cancer. And it subsequently exhibits pro-tumoral and treatment-resistant traits, which leads to difficulties in selecting salvage treatments and followed by dismal prognosis. Furthermore, since which salvage treatment can be selected and what the result of it will be determined by the prior treatment, there should be careful consideration in the initial therapeutic strategy. In this review, currently used treatment methods and results for locoregionally recurrent HNC are summarized, and considerations for each treatment based on the clinical and biomolecular characteristics of recurrent HNC are discussed. In addition, this review contains introductions of new therapeutic strategies including recent clinical trials and a perspective on the future direction for treatment of locoregionally recurrent HNC.
